FinCanna (CSE:CALI) has been profiled in an article published by CannabisFN (CFN) Media Group regarding the company’s progress in leading the charge in California’s licensed medical market. Describing FinCanna as a “royalty company specifically focused on the legal medical cannabis market,” the article also highlighted the company’s focus in developing a licensed medical cannabis campus in Coachella, California as part of their move to stay within the medical market.
The article also addressed the company’s response to the recent memo from US Attorney General Jeff Sessions. “FinCanna Capital and many other industry experts believe that the Sessions memo could actually pave the way to greater progress. In particular, the memo could create an impetus for members of both political parties to unify in efforts to create a clear federal policy further in support of the licensed medical cannabis industry.”
Lastly, the article discussed the company’s investment in Cultivation Technologies Inc (CTI). Under the terms of their investment, Fincanna will receive a royalty of 10 percent of CTI’s revenue from the Coachella facility and 50 percent of the profits from CTI’s interim extraction facility.
To read the full article, click here.
Click here to connect with FinCanna (CSE:CALI) for an Investor Presentation
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).